Can cosentyx impact flu shot's protective effects?

Short answer:
Yes—like many immune‑modulating drugs, Cosentyx (secukinumab) can modestly blunt the antibody response to an inactivated influenza shot. However, it does not eliminate the vaccine’s protective effect, and the shot is still strongly recommended (especially the inactivated, injectable vaccine, not the live nasal spray).

---

What the data say

| Question | Key findings | Practical take‑away |
|----------|--------------|---------------------|
| Does secukinumab affect flu‑vaccine response? | • Phase‑3 trials of secukinumab in psoriasis/psoriatic arthritis included sub‑studies of inactivated influenza vaccine.
• Most patients achieved protective antibody titers, but the rise in antibodies was a few percentage points lower compared with healthy controls.
• The reduction was clinically modest—patients still reached seroprotection rates above 70 % in most studies. | The vaccine still provides significant protection, but the immune response may be slightly less robust than in people not on biologics. |
| Are live vaccines safe? | Live‑attenuated influenza vaccine (the nasal spray) is contraindicated for anyone on secukinumab or other biologics that suppress cell‑mediated immunity. | Use the injectable, inactivated shot only. |
| Timing matters? | Some clinicians advise giving the flu shot 2–4 weeks before starting secukinumab, because the immune system is less suppressed then. If you’re already on therapy, give the vaccine at any point; the effect of the drug on the vaccine is usually stable over time. | If you’re starting secukinumab this year, vaccinate early. If you’re already on the drug, just get the shot when it’s due. |
| Does it affect other infections? | Secukinumab increases the risk of certain bacterial (especially Staphylococcus aureus) and fungal infections. It is not linked to a higher risk of viral infections like influenza. | The main benefit of vaccination remains—preventing flu in a patient whose immune system is partially suppressed. |

---

Why it matters

1. Reduced antibody titers → Potentially a slightly higher chance of catching the flu, especially if you’re in a high‑risk group (elderly, heart disease, diabetes, etc.).
2. Still protective → Most patients on secukinumab develop protective antibodies; the shot still lowers the risk of severe flu and its complications.
3. No increased side‑effects → The vaccine is well tolerated in patients on secukinumab; no significant increase in flu‑related adverse events has been observed.

---

Practical steps for patients on Cosentyx

1. Get the inactivated flu shot (the standard injectable vaccine) every flu season, even if you’re already on secukinumab.
2. Discuss timing with your rheumatologist/dermatologist: if you’re about to start secukinumab, aim to get the shot at least 2 weeks prior.
3. Follow routine precautions—hand hygiene, avoiding sick contacts, and consider a flu‑prevention plan if you have additional risk factors.
4. Ask about a booster—some guidelines suggest a second dose in high‑risk patients, especially if you have a weakened immune response.
5. Report any concerns—if you have a history of severe flu infections or immunodeficiency, talk with your provider about additional measures (e.g., antiviral prophylaxis during outbreaks).

---

Bottom line

- Cosentyx can slightly dampen the immune response to the flu vaccine, but the inactivated shot still provides meaningful protection.
- Always choose the injectable, inactivated vaccine—the nasal spray is unsafe for people on biologics.
- Work with your healthcare team to schedule the shot at the optimal time relative to your secukinumab dosing schedule.

If you have specific concerns about your immune status or vaccine timing, reach out to your prescribing clinician for personalized advice.